ChemoCentryx Competitors and Similar CompaniesClear all
ChemoCentryx's competitors and similar companies include Agios Pharmaceuticals, Pharmstandard, NATCO Pharma and Turning Point Therapeutics.
 ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. |  Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism. |  Pharmstandard Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products. |  NATCO Pharma NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API). |  Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. | |
Founding Date | Founding Date 1997 | Founding Date 2008 | Founding Date 2003 | Founding Date 1981 | Founding Date 2013 |
Type | Type Subsidiary | Type Public | Type Subsidiary | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations San Carlos, US HQ | Locations Cambridge, US HQ | Locations Dolgoprudny, RU HQ Kursk, RU Moscow, RU Petrovo Dalnee, RU Tomsk, RU Ufa, RU Vol'ginskii, RU | Locations Hyderabad, IN HQ Central Hope Town, IN Chennai, IN Hyderabad, IN Santola, IN Vijayapuri North, IN | Locations San Diego, US HQ |
Employees | Employees 51 | Employees 53611% increase | Employees 1,77814% increase | Employees 4,016 | Employees 474% decrease |
Financial | |||||
Revenue (est.) | Revenue (est.) $32.2m (FY, 2021) | Revenue (est.) $54m (FY, 2025) | Revenue (est.) ₽152.1b (FY, 2024) | Revenue (est.) ₹44.1b (FY, 2025) | Revenue (est.) $30.8m (FY, 2021) |
Cost of goods | Cost of goods $302k (FY, 2021) | Cost of goods $6.3m (FY, 2025) | Cost of goods ₽117b (FY, 2024) | Cost of goods ₹7.5b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $31.9m (FY, 2021) | Gross profit $47.7m (FY, 2025) | Gross profit ₽35.2b (FY, 2024) | Gross profit ₹37b (FY, 2025) | Gross profit N/A |
Net income | Net income ($131.8m) (FY, 2021) | Net income ($412.8m) (FY, 2025) | Net income ₽22.7b (FY, 2024) | Net income ₹18.8b (FY, 2025) | Net income ($236.6m) (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised $ 149.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 144.4m |
For sources of this data, please see the company profile
View Company Profiles
Agios Pharmaceuticals
HQ
Cambridge, US
Employees
536↑ 11% increase
Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
View companyPharmstandard
HQ
Dolgoprudny, RU
Pharmstandard (also known as АО Фармстандарт) is a company that develops and manufactures pharmaceutical products.
View companyNATCO Pharma
HQ
Hyderabad, IN
Employees
4,016
NATCO Pharma is a company focused on research, manufacturing, and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (API).
View companyTurning Point Therapeutics
HQ
San Diego, US
Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
View company